The Final Countdown, page-173

What prevents them from financing the R&D rebate?

Spend through March quarter was 3m plus right? .

Extrapolation gives what 3.8m for FY? 43.5% rebate? So net c1.65m

Ball park 10% for 8 monthss factoring costs say 1.15 to 1.45m ish?

Per previous CRO could have deferred payment in some form right?

So on assumption above is partially correct, I see potential to get to Nov or beyond here.

CR would therefore be a choice in near term. Good result's which these are (despite SP reaction) open up potential for CR at higher price, placement etc

Imo

DYOR